National Institute for Biological Standards and Control

What National Institute for Biological Standards and Control does

The National Institute for Biological Standards and Control (NIBSC) is a UK government executive agency operating as one of three centres within the Medicines and Healthcare products Regulatory Agency (MHRA), itself an executive agency of the Department of Health and Social Care. It discharges statutory functions under Section 57 of the Health and Social Care Act 2012 as the UK's national control laboratory for biological medicines. NIBSC produces and distributes the majority of the world's WHO International standards and biological reference materials, performs independent batch release testing of biological medicines prior to market release, and conducts regulatory science research. It operates two WHO Collaborating Centre designations (Biological Standardisation, Polio) and serves pharmaceutical manufacturers, pharmacopoeias, regulatory authorities, academic and research institutions, and advanced therapy developers across global markets.

Its core portfolio spans reference materials (WHO International standards, influenza standards, quality control reagents including CE-marked diagnostic controls), specialised reagent repositories (Centre for AIDS Reagents, Centre for Infectious Disease Reagents, CJD Resource Centre, UK Stem Cell Bank hosting EUTCD-grade human embryonic cell lines, and the WHO Collaborating Centre on Polio), and laboratory services (control/batch release testing, contract testing, customised biological materials, scientific and regulatory advice, and training events). Underlying capabilities include virology, bacteriology, biotherapeutics, analytical sciences, and advanced therapies. Supporting infrastructure includes a global online ordering system and the Result Reporting System (RRS) for digital delivery of batch release certificates.

NIBSC monetises through three streams: (1) handling, shipping, and insurance fees on reference materials provided at no cost for regulatory and research purposes; (2) contract testing services priced per project for therapeutics manufacturers and pharmacopoeias; and (3) expert services including customised biological materials, scientific and regulatory advice, and training events. As a public sector body, the organisation is also funded through UK government appropriations via DHSC/MHRA. Distribution is global via direct online ordering supplemented by account-based relationships managed by Commercial Project Managers. Distribution and research partnerships include WHO, MHRA, University College London, the TRANSVAC/TRANSVAC-DS and VAC2VAC European vaccine consortia, and South Korea's NIFDS.

Name

National Institute for Biological Standards and Control

Legal name

National Institute for Biological Standards and Control

Website

https://nibsc.org

Company type

Private

Founded year

1972

Operating status

Operating

Headcount range

51–100 employees

Short description

The National Institute for Biological Standards and Control (NIBSC) is a UK government agency operating within the MHRA that produces and distributes the majority of the world's WHO International standards and biological reference materials, performs independent batch release testing, and conducts regulatory science research for pharmaceutical manufacturers, pharmacopoeias, and regulatory authorities globally.

Ownership category

akta.pro rank

Product category

Regulatory Biological Reference Materials

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734)

akta.pro primary industry

National Public Health Reference Laboratories (HLAJAIAA)

akta.pro secondary industries

Microbiology & Infectious Disease Testing Laboratories (HLAFAMAD), Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB), Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), Drug Regulators (Human Pharmaceuticals) (HLAJADAA), Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

Keywords

• Biological reference materials
• WHO international standards
• Batch release testing
• Regulatory science services
• Biological standardisation

Headquarters

HQ city

Potters Bar

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain

Revenue model

1. Reference Materials and Standards: NIBSC provides biological reference materials including WHO International standards, influenza standards, and quality control reagents. While materials themselves are provided at no cost, handling fees, shipping costs, and associated transfer costs are charged to recipients.
2. Contract Testing Services: NIBSC offers contract testing services for external organisations including therapeutics manufacturers and pharmacopoeias, providing independent batch release testing and quality control assessment.
3. Expert Services: Provides customised biological materials, scientific and regulatory advice, and training and events services to pharmaceutical manufacturers and scientific organisations.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

NIBSC produces and distributes WHO International Standards and biological reference materials used globally for quality control of biological medicines, and performs independent batch release testing of biological medicines before market release. It also provides contract testing services, customised biological materials, scientific and regulatory advice, and training, alongside specialised reagent repositories (HIV/AIDS, influenza, polio, CJD, stem cells).

Product overview

NIBSC offers a unified portfolio of biological standards and regulatory science services. The core offering centres on WHO International Standards and biological reference materials, distributed globally for quality control of biological medicines. Supporting infrastructure includes specialized reagent repositories (Centre for AIDS Reagents, Centre for Infectious Disease Reagents, UK Stem Cell Bank, CJD Resource Centre), expert laboratory services (control/batch release testing, contract testing, scientific/regulatory advice), and educational programs. The organisation operates as part of the MHRA with WHO Collaborating Centre designations for polio and biological standardisation. Products include reference standards, cell lines, antibodies, recombinant proteins, and CE-marked quality control reagents, complemented by custom biological material generation and training workshops.

Differentiator

Problem solved

Functional benefit

Products and services

• WHO International Standards Globally recognised reference standards established by the World Health Organization for calibration and quality control of biological medicines, distributed by NIBSC as the world's major producer.
• Biological Reference Materials Catalogue Comprehensive catalogue of biological reference materials including WHO International standards, influenza standards, and quality control reagents used for testing and calibration of biological medicines.
• Control Testing Services Independent batch release testing services for biological medicines before market release, conducted by NIBSC as a regulatory control laboratory for manufacturers and regulatory authorities.
• UK Stem Cell Bank National repository and resource centre for stem cell lines including EUTCD-grade human embryonic cell lines, research grade stem cell lines, and Qualified Mouse Embryo Fibroblasts (MEFs), supporting advanced therapies research.
• Centre for AIDS Reagents (CFAR) Specialised resource providing HIV/AIDS research reagents including cell lines, viruses, antibodies, recombinant proteins, and clinical samples for HIV research worldwide.
• Centre for Infectious Disease Reagents Resource centre providing reagents for infectious disease research including COVID-19-related research reagents, supporting vaccine and diagnostic development.
• WHO Collaborating Centre on Polio WHO-designated centre conducting polio surveillance, quality control of polio vaccines, and supporting global polio eradication efforts.
• Influenza Resource Centre Comprehensive resource for influenza standardisation, seasonal and pandemic influenza research, potency testing, and reagent updates for vaccine development.
• CJD Resource Centre Research resource centre providing CJD reference reagents, test evaluations, amyloid research materials, and samples including brain protein 1433, spleen homogenates, and plasma panels for CJD diagnosis research.
• Customised Biological Materials Custom preparation and generation of biological reference materials tailored to specific organisational requirements for therapeutics manufacturers and pharmacopoeias.
• Contract Testing Services Specialised testing services for external organisations including biological products testing, pharmacopoeial testing, and regulatory compliance verification.
• Scientific and Regulatory Advice Expert consultation services providing scientific and regulatory guidance for biological medicines development, registration, and quality assurance.
• Training and Events Educational programs including workshops (Heparin Workshop, UK Stem Cell Bank workshop) and training events for industry professionals in biological standards and quality control.
• Quality Control Reagents Quality control reagents including CE-marked controls for clinical diagnostics such as Measles, Mumps, Lyme disease run controls, and multiplex diagnostic controls.
• Result Reporting System (RRS) Online system for reporting testing results related to control testing services and official batch release certificates.

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core and major.

• World Health Organization (WHO)coreStrategic or Co-development PartnerNIBSC operates as a WHO Collaborating Centre on Biological Standardisation and hosts the WHO Collaborating Centre on Polio. The organisation establishes WHO International standards and reference materials endorsed by WHO Expert Committee on Biological Standardisation.
• Medicines and Healthcare products Regulatory Agency (MHRA)coreStrategic or Co-development PartnerNIBSC merged with MHRA and operates as one of MHRA's three centres. MHRA is an executive agency of the Department of Health and Social Care.
• University College London (UCL)majorStrategic or Co-development PartnerNIBSC signed a collaboration agreement with UCL for joint working in scientific research and regulatory science.
• TRANSVAC ConsortiummajorStrategic or Co-development PartnerNIBSC is part of the TRANSVAC and TRANSVAC-DS consortium working towards a sustainable European vaccine infrastructure.
• VAC2VAC ConsortiummajorStrategic or Co-development PartnerNIBSC participates in the VAC2VAC consortium focused on vaccine quality control and reduction of animal testing.
• National Institute for Food and Drug Safety Evaluation (NIFDS) - South KoreamajorStrategic or Co-development PartnerNIBSC signed a Memorandum of Understanding with NIFDS to promote biological standardisation cooperation.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• European Directorate for the Quality of Medicines & HealthCare (EDQM): EDQM is the Council of Europe body that produces the European Pharmacopoeia reference standards and operates the Biological Standardisation Programme, making it the closest direct peer to NIBSC in establishing official biological reference materials and batch testing.
• Paul-Ehrlich-Institut (PEI): Germany's federal institute for vaccines and biomedicines performs independent batch release testing, WHO standardisation work, and regulatory science for biological medicines, mirroring NIBSC's mandate at a national level with similar global standing.
• National Institutes for Food and Drug Control (NIFDC, China): China's national control laboratory performs batch release testing and develops national reference standards for biologicals under NMPA, directly comparable to NIBSC's regulatory science function and explicitly mentioned in NIBSC's partnership network.
• Health Canada Biologics and Genetic Therapies Directorate: Health Canada's BGTD regulates and performs lot release testing for biological products in Canada, including vaccines and advanced therapies, making it a direct national-level peer to NIBSC for biological medicine oversight.
• National Institute of Infectious Diseases (NIID, Japan): Japan's NIID develops biological reference materials and conducts quality testing for vaccines and blood products under MHLW, serving as the Japanese counterpart to NIBSC's standards and infectious disease reagent work.

Broad incumbents

• FDA Center for Biologics Evaluation and Research (CBER): CBER is the US federal regulator for biologics, conducting lot release, developing reference materials, and setting standards for vaccines and advanced therapies; it is a broader incumbent that overlaps NIBSC's batch testing and standardisation remit at scale.

Regional players

• Therapeutic Goods Administration (TGA, Australia): TGA is Australia's regulator for biological medicines and a WHO-listed regulatory authority, performing lot release testing and standards-related work for the Australian market with globally comparable but regionally focused mandate.

Others

• Medicines and Healthcare products Regulatory Agency (MHRA): MHRA is NIBSC's parent executive agency and the broader UK regulator covering medicines, devices and blood products; it is included as a peer/parent context but does not directly compete, since NIBSC operates as one of MHRA's three centres.
• European Medicines Agency (EMA): EMA is the EU's central medicines regulator that licenses biological medicines across Europe but does not itself produce reference materials, making it an enabling regulatory peer rather than a direct competitor to NIBSC's standards work.
• World Health Organization (WHO): WHO establishes the framework for International Standards through its Expert Committee on Biological Standardisation and designates NIBSC as a collaborating centre, making WHO a framework-setting ecosystem participant rather than a direct competitor.

Market position

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/NIBSC_MHRA
• LinkedInlinkedin.com/company/nibsc

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about National Institute for Biological Standards and Control